AstraZeneca (AZN) to Release Earnings on Thursday

AstraZeneca (NASDAQ:AZN) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect AstraZeneca to post earnings of $1.14 per share and revenue of $14.7544 billion for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.08 billion. During the same period last year, the business earned $1.24 earnings per share. The firm’s revenue was up 16.1% on a year-over-year basis. On average, analysts expect AstraZeneca to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Price Performance

NASDAQ:AZN opened at $82.23 on Thursday. AstraZeneca has a 1-year low of $61.24 and a 1-year high of $86.57. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The firm has a fifty day simple moving average of $81.06 and a 200 day simple moving average of $74.82. The stock has a market capitalization of $255.03 billion, a PE ratio of 30.91, a P/E/G ratio of 1.52 and a beta of 0.36.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research note on Wednesday, July 9th. Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research report on Monday. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AZN. Brighton Jones LLC raised its stake in AstraZeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares in the last quarter. AQR Capital Management LLC raised its stake in AstraZeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after purchasing an additional 11,690 shares in the last quarter. Amundi raised its stake in AstraZeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after purchasing an additional 3,618 shares in the last quarter. Jump Financial LLC raised its stake in AstraZeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after purchasing an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in AstraZeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after purchasing an additional 559 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.